Paul Okunieff – författare

The International Society of Oxygen Transport to Tissue (ISOTT) was founded in 1973 to provide a forum for bioengineers, basic scientists, physiologists, and physicians to discuss new data, original theories, new interpretations of old data, and new technologies for the measurement of oxygen. At each annual meeting all posters are presented orally along with plenary lectures, and all presentations are given in a general session attended by everyone. Each meeting has had a specific focus, ranging from neonatology to physical chemistry to cancer biology. The Society has helped to build many careers, through opportunities to meet leaders in the field, and through awards made to young physicians and scientists. The Society also, through cross fertilization of ideas and scientific comradery, has inspired many breakthroughs in clinical medicine that now benefit mankind. I find myself president of the society after having been a winner of the Melvin Knisely Award for young scientists, in 1991. The 2003 meeting emphasized the role of oxygen and oxygen measurement in tumor growth, metastasis, physiology, and treatment resistance. Additionally, however, completely novel approaches to measurement of tissue oxygen were presented (notably work by Dr. Takahashi) and molecular methods for estimating tissue oxygen were evaluated. Papers discussing other aspects of oxygen measurement and pathophysiology were presented including in vivo ESR spectroscopy (notably including Dr. Swartz and colleagues), exercise physiology, organ transplant outcome (discussed by Dr. Cicco, our 2004 president), circulatory physiology, and cerebral oxygenation (notably including Dr. Chance).

This book cover all aspects of oxygen delivery to tissue, including blood flow and its regulation as well as oxygen metabolism. Special attention will be paid to methods of oxygen measurement in living tissue and application of these technologies to understanding physiological and biochemical basis for pathology related to tissue oxygenation. This book is multidisciplinary and designed to bring together experts and students from a range of research fields including biochemical engineering, physiology, microcirculation, and hematology.

The rapid advances in radiation oncology, radiation biology, and radiation therapy physics have led to an accumulation of information on the interactions of radiation with other therapeutic modalities, such as the wide array of chemotherapeutic agents being employed in combination with radiation therapy, as well as the multiple biologic response modi? ers that are being used in combination with radiation therapy. It is now recognized that they have a signi? cant impact on normal tissue toxicities. The radiation doses customarily deemed safe on the basis of past experience have now, when combined with other modalities, led to severe late effects in different vital organs. The previously de? ned radiation tolerance dosages remain as valuable guides, but their applicability has changed signi? cantly. The emphasis is now placed on the volume of the organ irradiated, as well as the dose being used. New constructs rel- ing global (whole organ) and focal (partial volume) injury as a function of the dose volume histogram emerge as a signi? cant predictor of late effects on normal tissues. There are now mathematical models such as the model on standard dose, time–dose factors, and accumulated radiation effects that have been supplanted by linear-q- dratic equations using the alpha/beta ratio and its clinical applicability to normal tissue complications. This volume presents contemporary data relating to late effects on normal tissues.

Multimodal treatment lies at the heart of the improvement in cancer cure rates. However, the more aggressive the treatment, the more adverse effects in normal tissues can be anticipated. Against this background, a major paradigm shift has taken place in that there is a new focus on cancer survivorship and quality of life: the life worth saving must be worth living. This volume is based on the CURED II conference held in May 2007, which was attended by scientists from many leading institutions. The volume comprises 18 chapters by leading experts who address a variety of important topics relating to late treatment effects, such as mechanisms and evolution of injury, risk factors, the role of screening, options for interventions, second malignancies, and prevention. It is hoped that it will assist the reader in understanding how to prevent and treat the long-term side-effects of irradiation, thus improving the quality of life of long-term survivors of cancer.

The rapid advances in radiation oncology, radiation biology, and radiation therapy physics have led to an accumulation of information on the interactions of radiation with other therapeutic modalities, such as the wide array of chemotherapeutic agents being employed in combination with radiation therapy, as well as the multiple biologic response modi? ers that are being used in combination with radiation therapy. It is now recognized that they have a signi? cant impact on normal tissue toxicities. The radiation doses customarily deemed safe on the basis of past experience have now, when combined with other modalities, led to severe late effects in different vital organs. The previously de? ned radiation tolerance dosages remain as valuable guides, but their applicability has changed signi? cantly. The emphasis is now placed on the volume of the organ irradiated, as well as the dose being used. New constructs rel- ing global (whole organ) and focal (partial volume) injury as a function of the dose volume histogram emerge as a signi? cant predictor of late effects on normal tissues. There are now mathematical models such as the model on standard dose, time–dose factors, and accumulated radiation effects that have been supplanted by linear-q- dratic equations using the alpha/beta ratio and its clinical applicability to normal tissue complications. This volume presents contemporary data relating to late effects on normal tissues.